Table 2.

Left ventricular function in control (Group I), CEL per se (Group II), BPS (Group III), CEL + BPS (Group IV).

Group	LVSP (mmHg)	LVEDP (mmHg)	LV(dp/dt) max (mmHgSec -1 )	LV(dp/dt) min (mmHgSec -1 )
I	109.10 ± 2.23	3.27 ± 0.44	10930.71 ± 824.12	-5892.81 ± 915.59
II	111.53 ± 1.96	10.21 ± 0.59**	6892.01 ± 407.67*	-3533.99 ± 314.10*
III	111.62 ± 3.07	6.28 ± 0.74	9970.62 ± 896.32	-5017.58 ± 497.15
IV	113.55 ± 1.54	4.49 ± 0.73*	11324.63 ± 875.04**	-6710.85 ± 688.41**

Values are expressed as mean ± SEM (n = 8) and analyzed by one-way ANOVA followed by Tukey-Kramer multiple comparison test.

^* p < 0.05 II v/s I, IV v/s II and

^** p < 0.01 II v/s I, IV v/s II . CEL: Celecoxib, BPS: Beraprost Sodium, LVSP: left ventricular systolic pressure, LVEDP: left ventricular end diastolic pressure, LV(dp/dt)_max: maximum rate of rise of left ventricular function, LV(dp/dt)_min: maximum rate of fall of left ventricular function.